Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Translabyrinthine Approach for Resection of Vestibular Schwannoma
Feng, Yening , Patel, Neil , Carlson, Matthew L. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 1, 2019 | Volume: 80 | Issue: S 03 | Pages: S286-S286

10.1055/s-0039-1677856 | PMID 31143593 Get It

Objectives This video describes the surgical indications, relevant anatomy, and surgical steps of routine translabyrinthine surgery for gross total resection of sporadic vestibular schwannoma. Design The procedure is presented through a surgical instructional video. Setting The surgery took place at tertiary skull base referral center. Parcipant A 47-year-old patient reported with nonserviceable hearing, frequent episodes of vertigo, recurrent severe headache, and a small unilateral right sided vestibular schwannoma. Results Gross total resection with preservation of facial nerve function was achieved. Conclusion This instructional video documents the surgical steps and relevant anatomy for translabyrinthine resection of vestibular schwannoma.The link to the video can be found at: https://youtu.be/CJ2vKMLs7aI.
SLC35A2‐CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported Individuals
Sosicka, Paulina , Agadi, Satish , Almannai, Mohammed , Bacino, Carlos A. , Barone, Rita , Burton, Jennifer, Carlston, Colleen M. , Cohen, Julie S. , Coman, David , Dipple, Katrina M. , Dorrani, Naghmeh, Dobyns, William B. , Elias, Abdallah F. , Epstein, Leon G. , Gahl, William A. , Garozzo, Domenico , Hammer, Trine Bjørg , Haven, Jaclyn, Héron, Delphine, Herzog, Matthew , Hoganson, George, Hunter, Jesse M. , Jain, Mahim , Juusola, Jane, Lakhani, Shenela , Lee, Hane , Lewis, Katherine, Mak, Christopher Chun Yu , McKnight, Dianalee , Mendelsohn, Bryce A. , Mignot, Cyril , Mirzaa, Ghayda , Mitchell, Wendy G. , Muhle, Hiltrud, Nelson, Stanley F. , Olczak, Mariusz , Palmer, Christina G.S. , Partikian, Arthur , Pierson, Tyler Mark , Regan, Brigid M. , Sacoto, María J. Guillen , Scaglia, Fernando , Scheffer, Ingrid E. , Segal, Devorah , Singhal, Nilika S. , Striano, Pasquale, Sturiale, Luisa , Symonds, Joseph D. , Willis, Mary , Wolfe, Lynne A. , Yano, Shoji , Powis, Zöe , Suchy, Sharon F., Edmondson, Andrew C. , Grünewald, Stephanie , Longo, Nicola , Mak, Christopher C Y , Patterson, Marc C. , Ross, M Elizabeth , Scheffer, Ingrid E , Symonds, Joseph , Edmondson, Andrew C , Ng, Bobby G. , Botto, Lorenzo D. , Chung, Hon-Yin B , Juusola, Jane , Lee, Joy Li-Yueh , Lewis, Katherine, Lourenco, Charles , Quinonez, Shane C. , Tang, Sha , Vilain, Eric J. N. , Yang, Hui , Rosenfeld, Jill A. , Freeze, Hudson H.

Mayo Clinic

Human Mutation | February 28, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/humu.23731 | PMID 30817854 Get It

Two-Stage Revision of Total Hip Arthroplasty for Infection Is Associated with a High Rate of Dislocation
McAlister, Ian P. , Perry, Kevin I. , Mara, Kristin C. , Hanssen, Arlen D. , Berry, Daniel J. , Abdel, Matthew P. , Abdel, Matthew P , Mara, Kristin C , Berry, Daniel J

Mayo Clinic

Journal of Bone and Joint Surgery | February 28, 2019 | Volume: 101 | Issue: 4 | Pages: 322-329

10.2106/jbjs.18.00124 | PMID 30801371 Get It

Background: Two-stage exchange is the most common form of treatment of chronic infection following total hip arthroplasty (THA). We examined the prevalence of, and risk factors associated with, hip instability following 2-stage exchange as well as the fate of reimplanted hip prostheses that dislocated. Methods: Data on 515 2-stage exchange THAs performed between 2000 and 2014 at a single institution were retrospectively reviewed. Risk factors for instability as well as postoperative reoperations and revisions were analyzed. The impact of dislocation on these outcomes was evaluated as well. The mean age at the time of reimplantation was 65 years, and the mean duration of follow-up was 5 years (range, 2 to 15 years). Results: Dislocation occurred in 52 hips following reimplantation (cumulative probability = 8.9% at 1 year). There was a higher risk of instability in women (hazard ratio [HR] = 1.8, p = 0.038) and in those who had a history of dislocation prior to the 2-stage revision (HR = 5.1, p < 0.001). Younger age, body mass index, number of previous operations, spacer type, surgical approach, use of a constrained liner, femoral head diameter, and persistent or recurrent infection were not found to be significant risk factors. Patients with an absent or ununited greater trochanter or abductor deficiency also had a higher rate of dislocation (HR = 30, p < 0.001), as did patients who underwent reimplantation with a megaprosthesis (HR = 6.0, p < 0.001). The risk of additional reoperations (HR = 121, p < 0.001) and revision surgery (HR = 13, p < 0.001) was significantly higher in patients who experienced a dislocation after the 2-stage exchange. Conclusions: Dislocation after 2-stage exchange THA continues to be a major concern, with the 1-year cumulative probability found to be 9% in the present study. Female sex, a history of dislocation, an absent or ununited greater trochanter or abductor deficiency, and reimplantation with a megaprosthesis were identified as risk factors for dislocation. There is a remarkable 121-fold increase in the rate of reoperations and a 13-fold increase in the rate of revisions in hips that dislocated after 2-stage exchange THA. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Host genetic variation in tumor necrosis factor and nuclear factor‐κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study
Wang, Sophia , Sarangi, Vivekananda , Link, Brian K. , Inwards, David J. , Witzig, Thomas E. , Rothman, Nathaniel , Asmann, Yan W. , Witzig, T.E. , Asmann, Yan, Cerhan, James R , Link, Brian K , Wang, Sophia S , Wang, Yucai , Habermann, Thomas M. , Maurer, Matthew J. , Feldman, Andrew L. , Cozen, Wendy , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

American Journal of Hematology | February 28, 2019 | Volume: 94 | Issue: 6 | Pages: No page available

10.1002/ajh.25451 | PMID 30815899 Get It

A multi-institutional analysis of presentation and outcomes for leptomeningeal disease recurrence after surgical resection and radiosurgery for brain metastases
Prabhu, Roshan S. , Turner, Brandon E. , Asher, Anthony L. , Marcrom, Samuel , Fiveash, John B. , Foreman, Paul M. , Patel, Kirtesh R., Curran, Walter J. , Breen, William G. , Brown, Paul D. , Grills, Inga S., Arden, Jessica D. , Foster, Lauren, Manning, Matthew A., Stern, Joseph D., Soltys, Scott G. , Burri, Stuart H., Turner, Brandon E , Press, Robert H. , Jethwa, Krishan R.

Mayo Clinic

Neuro-Oncology | February 27, 2019 | Volume: 21 | Issue: 8 | Pages: 1049-1059

10.1093/neuonc/noz049 | PMID 30828727 Get It

Abstract Background Radiographic leptomeningeal disease (LMD) develops in up to 30% of patients following postoperative stereotactic radiosurgery (SRS) for brain metastases. However, the clinical relevancy of this finding and outcomes after various salvage treatments are not known. Methods Patients with brain metastases, of which 1 was resected and treated with adjunctive SRS, and who subsequently developed LMD were combined from 7 tertiary care centers. LMD pattern was categorized as nodular (nLMD) or classical (“sugarcoating,” cLMD). Results The study cohort was 147 patients. Most patients (60%) were symptomatic at LMD presentation, with cLMD more likely to be symptomatic than nLMD (71% vs. 51%, P = 0.01). Salvage therapy was whole brain radiotherapy (WBRT) alone (47%), SRS (27%), craniospinal radiotherapy (RT) (10%), and other (16%), with 58% receiving a WBRT-containing regimen. WBRT was associated with lower second LMD recurrence compared with focal RT (40% vs 68%, P = 0.02). Patients with nLMD had longer median overall survival (OS) than those with cLMD (8.2 vs 3.3 mo, P < 0.001). On multivariable analysis for OS, pattern of initial LMD (nodular vs classical) was significant, but type of salvage RT (WBRT vs focal) was not. Conclusions Nodular LMD is a distinct pattern of LMD associated with postoperative SRS that is less likely to be symptomatic and has better OS outcomes than classical “sugarcoating” LMD. Although focal RT demonstrated increased second LMD recurrence compared with WBRT, there was no associated OS detriment. Focal cranial RT for nLMD recurrence after surgery and SRS for brain metastases may be a reasonable alternative to WBRT.
Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort
Gregory, Martin , Weaver, Kimberly N. , Hoversten, Patrick , Hicks, Stephen B., Patel, Devin , Ciorba, Matthew A. , Gutierrez, Alexandra, Beniwal‐Patel, Poonam , Palam, Sowmya , Syal, Gaurav , Christophi, George P. , Raffals, Laura E. , Deepak, Parakkal , Hicks, Stephen Bradley, Raffals, Laura, Deepak, Parakkal , Herfarth, Hans , Barnes, Edward L.

Mayo Clinic

Inflammatory Bowel Diseases | February 27, 2019 | Volume: 25 | Issue: 9 | Pages: 1569-1576

10.1093/ibd/izz030 | PMID 30810748 Get It

Abstract Background and Aims Inflammation of the pouch after ileal pouch-anal anastomosis (IPAA) can significantly impact quality of life and be difficult to treat. We assessed the effectiveness and safety of vedolizumab in Crohn’s disease (CD) of the pouch and chronic antibiotic-dependent or antibiotic-refractory pouchitis. Methods This was a retrospective, multicenter cohort study at 5 academic referral centers in the United States. Adult patients with endoscopic inflammation of the pouch who received vedolizumab were included. The primary outcome was clinical response at any time point. Secondary outcomes included clinical remission, endoscopic response, and remission. Univariate analysis and multivariate analysis were performed for the effect of the following variables on clinical response: fistula, onset of pouchitis less than 1 year after IPAA, younger than 35 years old, gender, previous tumor necrosis factor inhibitor-alpha use, and BMI &gt;30. Results Eighty-three patients were treated with vedolizumab for inflammation of the pouch between January 2014 and October 2017. Median follow-up was 1.3 years (interquartile range 0.7–2.1). The proportion of patients that achieved at least a clinical response was 71.1%, with 19.3% achieving clinical remission. Of the 74 patients with a follow-up pouchoscopy, the proportion of patients with endoscopic response and mucosal healing was 54.1% and 17.6%, respectively. Patients who developed pouchitis symptoms less than 1 year after undergoing IPAA were less likely to respond to vedolizumab, even after controlling for other risk factors. Conclusions Vedolizumab is safe and effective in the management of CD of the pouch and chronic pouchitis. Further studies are needed to compare vedolizumab with other biologic therapies for pouchitis and CD of the pouch.
False-Positive Serum Cocaine Screening Results in Patients Undergoing Evaluation for Renal Transplant
Snozek, Christine L.H. , Corey, Rebecca, Buras, Matthew , Johnson‐Davis, Kamisha L. , Corey, Rebecca L, Buras, Matthew R

Mayo Clinic

Journal of Analytical Toxicology | February 27, 2019 | Volume: 43 | Issue: 7 | Pages: 587-590

10.1093/jat/bkz019 | PMID 30929014 Get It

AbstractDrug screening during pre-transplant evaluations can have major implications for patient care, particularly because drug abuse has been associated with poor transplant outcomes. Although urine drug screening is usually preferred, serum testing is available for situations such as anuria due to end stage renal disease. However, there are few studies evaluating serum drug screening in specific populations such as patients undergoing kidney transplant evaluation. All serum drug screens ordered between January 2015 and November 2017 on patients being evaluated for renal transplant were compared against a large population of serum drug screens ordered from other institutions. Cocaine screening and confirmation results were evaluated to determine false positives. Cocaine screens were positive in 23 of 537 (4.3%) pre-transplant samples, and 211 of 5,115 (4.1%) comparison samples. Confirmation testing demonstrated that 14 (60.9%) pre-transplant samples were false positives, which was significantly (P < 0.01) higher than the rate of false positives in the comparison group (47/211, 22.3%). No common medication or other cross-reacting substance could be identified in the pre-transplant cohort to explain the false-positive results. Although serum cocaine screening had a low overall false-positive rate, the proportion of false positives was significantly higher in pre-transplant patients. Given the poor transplant outcomes associated with drug abuse, failure to properly interpret screening results as being false positives could negatively affect patient care. All members of the transplant team should recognize the importance of confirmation testing in this setting, to avoid unintended consequences due to false-positive screening results.
Improvement or Recovery From Sudden Sensorineural Hearing Loss With Steroid Therapy Does Not Preclude the Need for MRI to Rule Out Vestibular Schwannoma
Puccinelli, Cassandra L., Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | February 26, 2019 | Volume: 40 | Issue: 5 | Pages: 674-680

10.1097/mao.0000000000002171 | PMID 31083098 Get It

Objective:There is a common misconception that improvement in sudden sensorineural hearing loss (SSNHL) after treatment with steroid therapy effectively excludes the diagnosis of a vestibular schwannoma (VS) and such cases do not warrant an MRI. Paralleling this, steroids are commonly withheld for SSNHL in patients with an existing diagnosis of VS, believing that this condition is not steroid-responsive. This study seeks to underscore that improvement or recovery of SSNHL with steroid therapy does not exclude the diagnosis of VS and does not preclude the need for magnetic resonance imaging.Methods:A retrospective chart review was performed (2002–2017) of patients with previously untreated sporadic VS who developed SSNHL that improved after steroid treatment. A clinically significant audiometric improvement was defined as an increase of more than or equal to 15% in word recognition score (WRS) and/or decrease of more than or equal to 15 dB in 4-frequency pure-tone average (PTA). To supplement these data, a separate population of patients with incomplete or missing audiometric data, who reported unequivocal subjective improvement in hearing after steroid treatment, were also described to reinforce the study objective. Patient demographics, tumor characteristics, steroid regimen, and data regarding treatment response were recorded.Results:A total of 29 patients (55% women; median age of 47 yr) met inclusion criteria. Fourteen (48%) cases had objective audiometric documentation of SSNHL, while 15 (52%) had either subjective report only or incomplete audiometric data available. Eighteen (62%) had a single event, while 11 (38%) had more than one episode of SSNHL that was treated with steroids. For all patients, the median time between SSNHL and diagnosis of VS was 1.3 months (range, 0.13–148.4 mo). At the time of diagnosis, 15 tumors were purely intracanalicular, while 15 tumors had cerebellopontine angle extension. Of the latter, the median cisternal tumor size was 15.9 mm (range, 5.3–33). Twenty-six (90%) cases received oral steroid therapy alone, two (9%) had intratympanic steroid therapy alone, and one (3%) required combination therapy. The median PTA improvement with steroid therapy was 21 dB HL (range, –10–101.2) and the median WRS improvement was 40% (range, 4–100%).Conclusion:A therapeutic response to steroid therapy for SSNHL does not exclude the diagnosis of VS. All patients with SSNHL should undergo appropriate diagnostic imaging to prevent delays in diagnosis and potential treatment.
Influence of Selection Bias in Survey Studies Derived From a Patient-Focused Organization: A Comparison of Response Data From a Single Tertiary Care Center and the Acoustic Neuroma Association
Prummer, Christoph M., Kerezoudis, Panagiotis , Tombers, Nicole M. , Peris‐Celda, Maria , Link, Michael J. , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | February 26, 2019 | Volume: 40 | Issue: 4 | Pages: 504-510

10.1097/mao.0000000000002151 | PMID 30870367 Get It

Background: The Acoustic Neuroma Association (ANA) is a national, nonprofit organization, focused on the education and support of patients with vestibular schwannoma (VS). The aim of the present study is to characterize the profile of ANA survey respondents and compare them with non-ANA patients evaluated at a single tertiary academic referral center to investigate the potential influence of selection bias. Methods: A prospectively maintained VS quality-of-life (QOL) database, comprised of patients evaluated at the authors’ center and members of the ANA, was queried. Demographic variables, patient-reported symptoms and tumor characteristics, as well as patient-reported outcome scores were captured. Health-related QOL was evaluated using the disease-specific Penn Acoustic Neuroma QOL (PANQOL) questionnaire. Multivariable regression models were fitted for PANQOL domain and total scores as well as satisfaction with treatment adjusting for baseline demographics, symptoms, and PANQOL scores. Results: A total of 1,060 patients (802 [76%] ANA respondents) were analyzed. Overall, ANA patients were slightly younger (mean age: 59 vs 60 yr, p = 0.145), more likely to be women (72 vs 55%, p < 0.001), and had a larger tumor size (overall p < 0.001). Furthermore, a significantly higher proportion of ANA patients were more likely to undergo microsurgery (57 vs 21%) or radiation (21 vs 8%) and less likely to be managed with observation (16 vs 65%, overall p < 0.001). A significantly higher proportion of ANA patients reported hearing loss (95 vs 88%, p < 0.001), tinnitus (80 vs 73%, p = 0.034), dizziness (78 vs 64%, p < 0.001), headache (56 vs 45% p = 0.003), and facial paralysis (37 vs 12%, p < 0.001). On multivariable analysis, ANA respondents exhibited significantly lower PANQOL scores for hearing (OR: 0.47, 95% CI: 0.35–0.64, p < 0.001), balance (OR: 0.51, 95% CI: 0.38–0.70, p < 0.001), pain (OR: 0.63, 95% CI: 0.46–0.86, p = 0.004), facial function (OR: 0.58, 95% CI: 0.42–0.80, p = 0.001), energy (OR: 0.44, 95% CI: 0.32–0.59, p < 0.001), anxiety (OR: 0.54, 95% CI: 0.40–0.74, p < 0.001), general (OR: 0.72, 95% CI: 0.53–0.98, p = 0.03), and total QOL (OR: 0.40, 95% CI: 0.30–0.55, p < 0.001). No statistically significant difference was seen with regard to treatment satisfaction. To determine the true clinical relevance of these differences, the two groups were compared using the minimal clinically important difference (MCID) for each domain. MCID is defined as the smallest difference in score in the domain of interest that patients perceive as important, either beneficial or harmful. The domains for hearing, balance, energy, anxiety, and total QOL reached their respective MCID thresholds, indicating that the ANA cohort has QOL scores that are clinically, perceptually worse for these domains compared to the non-ANA group. Conclusion: These data help delineate some of the inherent limitations and biases associated with survey studies incorporating data from national patient support organizations. The population profile of ANA survey respondents likely differs significantly from the greater population of patients with VS that may be encountered at a tertiary referral center.
Genetically Engineered Neoplastic Cerebral Organoids – A New Frontier in Preclinical Cancer Research
Hess, Ryan Falcone, Abi-Aad, Karl R., Welz, Matthew E., Bendok, Bernard R. , Hess, Ryan, Hess, Ryan

Mayo Clinic

Neurosurgery | February 25, 2019 | Volume: 85 | Issue: 2 | Pages: E172-E173

10.1093/neuros/nyz028 | PMID 30860263 Get It